Lobe Sciences Ltd. is a biopharmaceutical company, which engages in the discovery and development of transformative medicines to treat rare diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-06-19. The Company, through its wholly owned subsidiaries, Alera Pharma, Inc. and Altemia, Inc., is advancing the development of a patented drug candidate aimed at treating neurological disorders, with an initial focus on chronic cluster headache (Alera). The firm commercializes Altemia MF, a medical food designed to manage deficiencies commonly found in sickle cell disease. Additionally, through Cynaptec Pharmaceuticals, Inc. (Cynaptec), the Company retains an interest in developing Conjugated Psilocin in neurology and psychiatric indications. Conjugated Psilocin is a patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
Follow-Up Questions
Who is the CEO of Lobe Sciences Ltd?
Dr. Frederick Sancilio is the Chairman of the Board of Lobe Sciences Ltd, joining the firm since 2024.
What is the price performance of LOBEF stock?
The current price of LOBEF is $0.0349, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Lobe Sciences Ltd?
Lobe Sciences Ltd belongs to N/A industry and the sector is N/A
